Showing results (321-330 of 332) with videos related to
Sort By:
Pageof 34
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 5, 2001
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primateG B Stroup, M W Lark, D F Veber, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2001
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized ratM W Lark, G B Stroup, R A Dodds, et al.European Journal of Neurology|July 22, 2014
Outcomes of intravenous tissue plasminogen activator for acute ischaemic stroke in HIV-infected adultsE M Sweeney, K T Thakur, J L Lyons, et al.Medicinal Research Reviews|February 27, 2001
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.Bone|May 9, 2002
A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized ratMichael W Lark, G B Stroup, I E James, et al.The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.Journal of the Neurological Sciences|March 3, 2021
Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapyM Garcia-Montojo, S Fathi, G Norato, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonistK W Ward, L M Azzarano, W E Bondinell, et al.Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonistsR M Keenan, W H Miller, M A Lago, et al.Pageof 34